Sharekhan

Lyka Labs Ltd

Tue 29/04/2025,15:47:14 | NSE : LYKALABS

₹ 111.46-0.60 (-0.54%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 112.00

Previous Close

₹ 112.06

Volume

18193

Mkt Cap ( Rs. Cr)

₹397.80

High

₹ 113.50

Low

₹ 109.99

52 Week High

₹ 176.59

52 Week Low

₹ 96.80

Book Value Per Share

₹ 27.71

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Lyka Labs Ltd

Your Vote -

Buy

57.14%

Hold

28.57%

Sell

14.29%

57.14%

14 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

121.65

1000

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

1000

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Lyka Labs Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Lyka Labs - Updates

    18 Apr 2025, 4:43PM Lyka Labs Limited has informed the Exchange regarding '-Intimation for change of email id and website details of Registrar & Share Transfer Agent '.
  • Lyka Labs - -Intimation For Change Of Email Id And Website Details Of Registrar & Share Transfer Agent

    18 Apr 2025, 3:53PM As per letter attached
  • Lyka Labs has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    15 Apr 2025, 7:00AM As of March 2025, 58.16% is owned by Indian Promoters and 41.84% by Public. <p align=justify> Institutional holds 0.90% (Insurance Companies 0.28%) an
  • Lyka Labs - Copy of Newspaper Publication

    10 Apr 2025, 4:28PM Lyka Labs Limited has informed the Exchange about Copy of Newspaper Publication
  • Lyka labs secures patent for Innovative Pregabalin Gel 8%

    8 Apr 2025, 12:38PM Lyka Labs Limited is proud to announce the grant of an Indian Patent for its novel formulation, Pregabalin Gel 8%, with patent protection extending un
  • Lyka Labs - Press Release

    8 Apr 2025, 11:31AM Lyka Labs Limited has informed the Exchange regarding a press release dated April 08, 2025, titled ""Intimation under Regulation 30 of SEBI (Listing O
  • Lyka Labs - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    8 Apr 2025, 11:23AM As per letter attached
  • Lyka Labs - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    4 Apr 2025, 6:15PM Lyka Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Lyka Labs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    4 Apr 2025, 3:41PM As per letter attached
  • Lyka Labs - Disclosure under SEBI Takeover Regulations

    2 Apr 2025, 6:50PM Ipca Laboratories Ltd has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substan
  • Lyka Labs - Disclosure under SEBI Takeover Regulations

    2 Apr 2025, 6:26PM Lyka Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial
  • Lyka Labs - General Updates

    1 Apr 2025, 5:34PM Lyka Labs Limited has informed the Exchange about General Updates
  • Lyka Labs - Update On The Scheme Of Amalgamation

    1 Apr 2025, 5:50PM As per letter attached
  • Lyka Labs - Disclosure under SEBI Takeover Regulations

    26 Mar 2025, 5:09PM Lyka Labs Limited has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisition ma
  • Lyka Labs - Disclosure under SEBI Takeover Regulations

    26 Mar 2025, 2:26PM Kunal Narendra Gandhi has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in respect of any acquisitio
  • Lyka Labs - Trading Window-XBRL

    26 Mar 2025, 11:23AM LYKA LABS LIMITED has informed the Exchange about Closure of Trading Window
  • Lyka Labs - Trading Window

    26 Mar 2025, 11:20AM Lyka Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
  • Lyka Labs - Shareholders meeting

    5 Mar 2025, 3:55PM Voting results of the meeting of the Preference Shareholders of the Companyconvened on Tuesday, 4th March 2025, as per the NCLT Order
  • Lyka Labs - Shareholders meeting

    5 Mar 2025, 3:52PM Voting results of the meeting of the Unsecured Creditors of the Companyconvened as per the NCLT order on Tuesday, 4th March 2025
  • Lyka Labs - Shareholders meeting

    5 Mar 2025, 3:49PM Voting results of the meeting of the Secured Creditors of the Company conveyedas per the NCLT order on Tuesday, 4th March 2025
  • Lyka Labs - Shareholders meeting

    5 Mar 2025, 3:43PM Lyka Labs Limited has submitted the Exchange a copy Srutinizers report of Court Convened General Meeting held on March 04, 2025
  • Lyka Labs - Voting Results Of The Meeting Of The Preference Shareholders Of The Company Convened On Tuesday, 4Th March 2025,

    5 Mar 2025, 3:26PM As per letter attached
  • Lyka Labs - Voting Results Of The Meeting Of The Unsecured Creditors Of The Company Convened As Per The NCLT Order On Tuesday

    5 Mar 2025, 3:14PM As per letter attached
  • Lyka Labs - Voting Results Of The Meeting Of The Secured Creditors Of The Company Convened As Per The NCLT Order On Tuesday,

    5 Mar 2025, 2:52PM As per letter attached.
  • Lyka Labs - Voting Results Of The Meeting Of The Equity Shareholders Of The Company For Court Convened Meeting Held On Tuesda

    5 Mar 2025, 2:06PM As per letter attached
  • Lyka Labs - Shareholders meeting

    4 Mar 2025, 5:55PM Lyka Labs Limited has informed the Exchange regarding Proceedings of Court Convened General Meeting held on March 04, 2025 along with a copy of minut
  • Lyka Labs - Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting

    4 Mar 2025, 5:46PM Summary of proceedings of the Meeting of Equity Shareholders, Secured Creditors, Unsecured Creditors and Preference Shareholder of Company convened p
  • Lyka Labs - Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements)\r\nRegulations, 2015\r\n\r\n Intimat

    27 Feb 2025, 6:56PM As per letter attached
  • Lyka Labs - Action(s) initiated or orders passed

    27 Feb 2025, 6:50PM Lyka Labs Limited has informed the Exchange about Action(s) initiated or orders passed
  • Lyka Labs - General Updates

    26 Feb 2025, 10:14AM Lyka Labs Limited has informed the Exchange about General Updates
  • Lyka Labs - Credit Rating Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regula

    26 Feb 2025, 9:44AM As per attached letter
  • Lyka Labs - Notice Of Shareholders Meetings-XBRL

    13 Feb 2025, 12:52PM Lyka Labs Limited has informed the Exchange about Notice of Shareholders Meeting for NCLT/ Court Convened Meeting to be held on 04-Mar-2025
  • Lyka Labs - Copy of Newspaper Publication

    5 Feb 2025, 3:36PM Lyka Labs Limited has informed the Exchange about Copy of Newspaper Publication
  • Lyka Labs - Integrated Filing- Financial

    5 Feb 2025, 3:29PM Integrated Filing (Financial) for the third quarter and nine months ended 31st December, 2024
  • Lyka Labs - Integrated Filing (Financial)

    5 Feb 2025, 3:06PM As per letter attached
  • Lyka Labs - Financial Result Updates

    4 Feb 2025, 3:25PM Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Lyka Labs - Outcome of Board Meeting

    4 Feb 2025, 3:20PM Lyka Labs Limited has informed the Exchange regarding Outcome of Board Meeting held on February 04, 2025.
  • Lyka Labs Q3 net profit jumps 98.53% at Rs 2.70 cr

    4 Feb 2025, 3:41PM The company reported standalone net profit of Rs 2.70 crore for the quarter ended December 31, 2024 as compared to Rs 1.36 crore in the same period la
  • Lyka Labs - Intimation Under Regulations 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations,

    4 Feb 2025, 3:11PM As per letter attached
  • Lyka Labs - Board Meeting Outcome for Outcome Of The Board Meeting - 4Th March, 2025

    4 Feb 2025, 3:07PM As per letter attached
  • Lyka Labs - Copy of Newspaper Publication

    31 Jan 2025, 6:13PM Lyka Labs Limited has informed the Exchange about Copy of Newspaper Publication
  • Lyka Labs - Shareholders meeting

    31 Jan 2025, 6:09PM Lyka Labs Limited has informed the Exchange regarding Notice of Court Convened General Meeting to be held on March 04, 2025
  • Lyka Labs - Notice Of Meeting Of Secured Creditors Pursuant To The Order Of Hon'Ble National Company Law Tribunal Division Be

    31 Jan 2025, 5:46PM As per letter attached
  • Lyka Labs - Notice Of Meeting Of Secured Creditors Pursuant To The Order Of Hon'Ble National Company Law Tribunal Division Be

    31 Jan 2025, 5:45PM As per letter attached
  • Lyka Labs - Notice Of Meeting Of Unsecured Creditors Pursuant To The Order Of Hon'Ble National Company Law Tribunal Division

    31 Jan 2025, 5:33PM As per letter attached
  • Lyka Labs - Shareholders meeting

    31 Jan 2025, 5:07PM Lyka Labs Limited has informed the Exchange regarding Notice of Court Convened General Meeting to be held on March 04, 2025
  • Lyka Labs - Shareholders meeting

    31 Jan 2025, 4:56PM Lyka Labs Limited has informed the Exchange regarding Notice of Court Convened General Meeting to be held on March 04, 2025
  • Lyka Labs - Shareholders meeting

    31 Jan 2025, 4:52PM Lyka Labs Limited has informed the Exchange regarding Notice of Court Convened General Meeting to be held on March 04, 2025
  • Lyka Labs - Shareholders meeting

    31 Jan 2025, 4:47PM Lyka Labs Limited has informed the Exchange regarding Notice of Court Convened General Meeting to be held on March 04, 2025
  • Lyka Labs - Notice Of Meeting Of Preference Shareholders Pursuant To The Order Of Hon'Ble National Company Law Tribunal Divis

    31 Jan 2025, 4:14PM As per letter attached
  • Lyka Labs - Notice Of Meeting Of Equity Shareholders Pursuant To The Order Of Hon'Ble National Company Law Tribunal Division

    31 Jan 2025, 4:06PM As per letter attached
  • Lyka Labs - Intimation Of Dispatch Of Notices For Shareholders' And Creditors' Meetings Pursuant To The Order Of Hon'Ble Nati

    31 Jan 2025, 4:02PM As per letter attached
  • Lyka Labs gets CDSCO nod to manufacture & market Tofacitinib Ointment

    10 Oct 2023 , 12:01PM Lyka Labs receives Central Drugs Standard Control Organisation nod to manufacture & market Tofacitinib ointment

Key fundamentals

Evaluate the intrinsic value of Lyka Labs Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 155.8986 147.4678 172.6534 165.5541 155.0602
Liabilities 155.8986 147.4678 172.6534 165.5541 155.0602
Equity 33.09 30.69 28.69 28.69 28.69
Gross Profit 14.5604 15.6005 97.4991 14.4256 -3.2152
Net Profit -2.2689 -13.2866 39.9023 -14.4589 -55.3865
Cash From Operating Activities 3.0895 6.8748 76.5342 5.7503 -11.4484
NPM(%) -2.13 -16.48 24.27 -23.22 -135.93
Revenue 106.3963 80.5926 164.3488 62.263 40.7434
Expenses 91.8359 64.9921 66.8497 47.8374 43.9586
ROE(%) -2.29 -13.43 40.34 -14.61 -55.99

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Lyka Labs Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 840.85 0.23 11.87 63.95 1321.50 1.37
Lotus Eye Hospital and Institute Ltd 81.36 2.94 339.00 233.02 14.01 0.61
Vaishali Pharma Ltd 13.72 -0.15 457.33 120.11 2.76 0.00
Astec Lifesciences Ltd 693.05 -1.61 0.00 219.72 -687.11 0.00

Company Info

YEAR EVENTS 1976 - The company was incorporated on 29th December as a private Limited Company and Converted into a Public Limited company on 19th December, 1985. - The company alongwith Gujarat Industrial Investment Corporation Limited promoted a new company, Gujarat Lyka Organics Limited, at Ankleshwar in Gujarat for the manufacture of Semi-Synthetic Penicilline. 1993 - The Company proposed to offer 20,60,000 No. of Equity Shares of Rs. 10/- each at an issue price not exceeding Rs. 35/- per share on the basis of one Equity Share for every two Equity Shares. 1994 - The company is negtiating tieup arrangements with internationally reputed manufactureres for marketing and manufacturing its products in India. 1995 - Government of India has selected the Company for the award of the Certificate of Merit for the excellent export performance during 1993-94. Further CHEMEXCIL has also selected the Company for the SECOND AWARD for outstanding export performance during 1993-94. - The Company has commenced production at its new formulation plant at Tarapur, have been designed with state-of-the-art technology to meet with the International Standards of Good Manufacturing Practices and with Total Quality Management Systems (TOM). - The Company has also set up additional manufacturing facility for ointment at Ankleshwar - Lyka Exports Limited became a subsidiary of the Company. - The Company allotted 1,50,000 Equity Shares to Foreign Institutional Investors on private placement basis and 40,000 Equity Shares to the Promoters. 1997 - The Company during the period has allotted 5,65,000 Secured Redeemable Non-Convertible Debentures of Rs.100/- each aggregating to Rs.5.65 crores. - Lyka Labs Limited has entered into the marketing of skin cream which is used to treat dry skin conditions. - The company has recently launched a rubefacient, too. 1998 - The Company's Administrative Office and Corporate Quality Assurance at Mumbai and Plant at Tarapur has been awarded ISO 9002 Certification for its Quality Management System by SGS Yarsley International Certification Services Limited, U.K. 1999 - Lyka Labs has launched a product-rationalisation exercise to exit cardiovasculars which is a non-focus area, sources opine. - The company recently launched dermatological skin ointment Cetraben. 2000 - The Company to issue on preferential basis 30,00,000 No. of equity shares of Rs. 10/- each on preferential allotment to Financial Institutions/FIIs/MFs. 2003 -Entered into an agreement with BDR Pharmaceuticals International to form a 50:50 joint venture. The new company will be focussed on enhancing Lyka's export business to developed and developing countries, which at present being handled by Lyka. -Lyka Labs marketing tie-up with Bio X-Healthcare -Lyka Labs Ltd has informed that the Company has decided to dis-invest its holding in its subsidary, Lyka Exports Ltd. In view of this, Lyka Exports Ltd. will cease to be its subsidary. 2005 -Lyka Labs launches BIOXTRA Toothpaste & Gel -Clearwater Capital Partners Limited joined hands with Lyka Labs Ltd 2006 -Lyka Labs Ltd has informed that Lyka Labs Ltd has changed the Registrar and Transfer Agent from MCS Ltd to Sharex Dynamic ( India ) Limited, Unit No.1, Luthra Ind. Premises, Andheri Kurla Road, Safed Pool, Andheri ( East ) Mumbai 400 072, Tel No. 2851 5606/44 Fax 2851 2885, with effect from September 30, 2006. 2008 -Lyka Labs Ltd has appointed Mr. D G Shah as Additional Director of the Company. 2009 - Lyka Labs Ltd has re-appointed Shri. N. I. Gandhi as Managing Director of the Company w.e.f. 1st April, 2009, subject to approval of the Central Government. 2010 - Lyka Labs Ltd has appointed Mr. Manish Jaywant as CFO w.e.f. June 01, 2010. 2011 - The Company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council. - The Company has entered MOU with European based Company for Transfer Known- How / Technology to manufacture lyophilized product. 2012 - Email ID : investorredressal@lykalabs.com 2014 -Mr. Yogesh B. Shah has been appointed as Chief Finance Officer. 2016 -Lyka Healthcare Limited, an entirely owned subsidiary of Lyka Labs Limited, has launched two domestic marketing divisions. 2017 -Amalgamation of Lyka Healthcare Ltd. (Transferor Company) being the wholly owned subsidiary with Lyka Labs Ltd. (Transferee Company). 2021 -"Merger of Lyka Exports Limited with Lyka Labs Limited".

YEAR EVENTS 1976 - The company was incorporated on 29th December as a private Limited Company and Converted into a Public Limited company on 19th December, 1985. - The company alongwith Gujarat Industrial Investment Corporation Limited promoted a new company, Gujarat Lyka Organics Limited, at Ankleshwar in Gujarat for the manufacture of Semi-Synthetic Penicilline. 1993 - The Company proposed to offer 20,60,000 No. of Equity Shares of Rs. 10/- each at an issue price not exceeding Rs. 35/- per share on the basis of one Equity Share for every two Equity Shares. 1994 - The company is negtiating tieup arrangements with internationally reputed manufactureres for marketing and manufacturing its products in India. 1995 - Government of India has selected the Company for the award of the Certificate of Merit for the excellent export performance during 1993-94. Further CHEMEXCIL has also selected the Company for the SECOND AWARD for outstanding export performance during 1993-94. - The Company has commenced production at its new formulation plant at Tarapur, have been designed with state-of-the-art technology to meet with the International Standards of Good Manufacturing Practices and with Total Quality Management Systems (TOM). - The Company has also set up additional manufacturing facility for ointment at Ankleshwar - Lyka Exports Limited became a subsidiary of the Company. - The Company allotted 1,50,000 Equity Shares to Foreign Institutional Investors on private placement basis and 40,000 Equity Shares to the Promoters. 1997 - The Company during the period has allotted 5,65,000 Secured Redeemable Non-Convertible Debentures of Rs.100/- each aggregating to Rs.5.65 crores. - Lyka Labs Limited has entered into the marketing of skin cream which is used to treat dry skin conditions. - The company has recently launched a rubefacient, too. 1998 - The Company's Administrative Office and Corporate Quality Assurance at Mumbai and Plant at Tarapur has been awarded ISO 9002 Certification for its Quality Management System by SGS Yarsley International Certification Services Limited, U.K. 1999 - Lyka Labs has launched a product-rationalisation exercise to exit cardiovasculars which is a non-focus area, sources opine. - The company recently launched dermatological skin ointment Cetraben. 2000 - The Company to issue on preferential basis 30,00,000 No. of equity shares of Rs. 10/- each on preferential allotment to Financial Institutions/FIIs/MFs. 2003 -Entered into an agreement with BDR Pharmaceuticals International to form a 50:50 joint venture. The new company will be focussed on enhancing Lyka's export business to developed and developing countries, which at present being handled by Lyka. -Lyka Labs marketing tie-up with Bio X-Healthcare -Lyka Labs Ltd has informed that the Company has decided to dis-invest its holding in its subsidary, Lyka Exports Ltd. In view of this, Lyka Exports Ltd. will cease to be its subsidary. 2005 -Lyka Labs launches BIOXTRA Toothpaste & Gel -Clearwater Capital Partners Limited joined hands with Lyka Labs Ltd 2006 -Lyka Labs Ltd has informed that Lyka Labs Ltd has changed the Registrar and Transfer Agent from MCS Ltd to Sharex Dynamic ( India ) Limited, Unit No.1, Luthra Ind. Premises, Andheri Kurla Road, Safed Pool, Andheri ( East ) Mumbai 400 072, Tel No. 2851 5606/44 Fax 2851 2885, with effect from September 30, 2006. 2008 -Lyka Labs Ltd has appointed Mr. D G Shah as Additional Director of the Company. 2009 - Lyka Labs Ltd has re-appointed Shri. N. I. Gandhi as Managing Director of the Company w.e.f. 1st April, 2009, subject to approval of the Central Government. 2010 - Lyka Labs Ltd has appointed Mr. Manish Jaywant as CFO w.e.f. June 01, 2010. 2011 - The Company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council. - The Company has entered MOU with European based Company for Transfer Known- How / Technology to manufacture lyophilized product. 2012 - Email ID : investorredressal@lykalabs.com 2014 -Mr. Yogesh B. Shah has been appointed as Chief Finance Officer. 2016 -Lyka Healthcare Limited, an entirely owned subsidiary of Lyka Labs Limited, has launched two domestic marketing divisions. 2017 -Amalgamation of Lyka Healthcare Ltd. (Transferor Company) being the wholly owned subsidiary with Lyka Labs Ltd. (Transferee Company). 2021 -"Merger of Lyka Exports Limited with Lyka Labs Limited".

Read More

Parent Organisation

Lyka Labs Ltd.

Founded

29/12/1976

Managing Director

Mr.Kunal Gandhi

NSE Symbol

LYKALABSEQ

FAQ

The current price of Lyka Labs Ltd is ₹ 111.46.

The 52-week high for Lyka Labs Ltd is ₹ 113.50 and the 52-week low is ₹ 109.99.

The market capitalization of Lyka Labs Ltd is currently ₹ 397.80. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Lyka Labs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Lyka Labs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Lyka Labs Ltd shares.

The CEO of Lyka Labs Ltd is Mr.Kunal Gandhi, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT